Needham & Company LLC reissued their hold rating on shares of Inogen (NASDAQ:INGN - Free Report) in a report published on Wednesday,Benzinga reports.
Separately, StockNews.com lowered shares of Inogen from a "buy" rating to a "hold" rating in a research note on Wednesday, February 26th.
Get Our Latest Stock Report on INGN
Inogen Price Performance
INGN traded down $0.10 during midday trading on Wednesday, hitting $7.21. 67,255 shares of the company's stock traded hands, compared to its average volume of 239,847. The company has a market cap of $193.86 million, a PE ratio of -3.20 and a beta of 1.48. The stock's fifty day simple moving average is $8.33 and its 200-day simple moving average is $9.22. Inogen has a one year low of $6.40 and a one year high of $13.33.
Hedge Funds Weigh In On Inogen
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in shares of Inogen by 2.7% in the third quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company's stock valued at $8,692,000 after purchasing an additional 23,891 shares during the last quarter. Barclays PLC raised its holdings in Inogen by 72.9% in the 3rd quarter. Barclays PLC now owns 55,508 shares of the medical technology company's stock valued at $539,000 after acquiring an additional 23,398 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Inogen by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company's stock worth $5,377,000 after acquiring an additional 5,921 shares during the period. Franklin Resources Inc. acquired a new stake in shares of Inogen during the 3rd quarter worth approximately $139,000. Finally, State Street Corp increased its position in shares of Inogen by 2.8% during the third quarter. State Street Corp now owns 511,018 shares of the medical technology company's stock valued at $4,957,000 after purchasing an additional 14,054 shares during the period. Institutional investors and hedge funds own 89.94% of the company's stock.
Inogen Company Profile
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
